Update on the prevention of type 2 diabetes (Q37810507)

23 August 2017

Update on the prevention of type 2 diabetes (English)

1 reference

23 August 2017

0 references

Jocelyne G Karam

1

1 reference

PubMed ID

21086076

23 August 2017

Samy I McFarlane

series ordinal

2

1 reference

23 August 2017

1 February 2011

1 reference

23 August 2017

Current diabetes report

1 reference

23 August 2017

11

1 reference

23 August 2017

1

1 reference

23 August 2017

56-63

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-010-0163-x

23 August 2017

0 references

cites work

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Prevention of type 2 diabetes: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Diabetes, hypertension, and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Prevention of type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Impaired fasting glucose and impaired glucose tolerance: implications for care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effects of exercise on insulin sensitivity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of weight loss with lifestyle intervention on risk of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Meta-analysis: metformin treatment in persons at risk for diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Lipid-lowering agents and new onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Surgery as an intervention for obesity. Results from the Swedish obese subjects study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-010-0163-X

Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study

21 January 2018

1 reference

12 December 2020

Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program

1 reference

12 December 2020

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

1 reference

12 December 2020

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

1 reference

12 December 2020

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

1 reference

12 December 2020

Gender disparities in the control of cardiovascular risk factors in people with diabetes

1 reference

12 December 2020

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

10.1007/S11892-010-0163-X

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21086076